Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections

Tso, Winnie W. Y.; Kwan, Mike Yat Wah; Wang, Yu Liang; Leung, Lok Kan; Leung, Daniel; Chua, Gilbert T.; Ip, Patrick; Fong, Daniel Yee Tak; Wong, Wilfred Hing Sang; Chan, Sophelia H.S.; Chan, Jasper Fuk‐Woo; Peiris, Malik; Lau, Yu Lung; Duque, Jaime S. Rosa

doi:10.1080/22221751.2022.2093135

Cited by 48 publications

(80 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While some data have shown Omicron to lead to higher morbidity among unvaccinated and/or previously uninfected children as compared to influenza/parainfluenza infections [ 8 ], our register did not include data regarding vaccination status, prior COVID-19 disease, and/or comorbidities. According to Edwards et al, Omicron is independently associated with ICU admission and severe disease, as defined by the WHO Clinical Progression Scale in children without SARS-CoV-2 immunization or prior COVID-19 infection [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Doenhardt

Gano

Sorg

et al. 2022

Viruses

View full text Add to dashboard Cite

(1) Background: When the Omicron variant of SARS-CoV-2 first emerged in Germany in January 2022, data on related disease severity among children and adolescents were not yet available. Given Omicron’s high transmissibility, the ability to assess its impact on admission and hospitalization rates in children’s hospitals is critical for the purpose of understanding the scope of its burden on the German healthcare system. (2) Methods: From 24 January 2022 to 31 July 2022, SARS-CoV-2 cases admitted to German pediatric hospitals were monitored via a national, clinician-led reporting system (CLRS) established by the German Society for Pediatric Infectious Diseases (DGPI). Cases treated on general wards and intensive care units, as well as patient age and the need for respiratory support, were recorded. (3) Results: From January to July 2022, a median of 1.7 cases (range 0.4–3) per reporting pediatric hospital per day was hospitalized in general wards, whereas a median of 0.1 cases (range 0–0.4 cases) was admitted to intensive care units. Of all hospitalized patients, 4.2% received respiratory support. (4) Conclusions: Despite the high incidence rates documented in connection with the Omicron variant in early 2022, the number of pediatric hospital admissions, and especially the number of cases with the need for intensive care treatment and respiratory support due to symptomatic SARS-CoV-2 infection, remained relatively low. Higher Omicron incidence rates had only a modest impact on SARS-CoV-2-related admissions and hospitalization in German children’s hospitals.

show abstract

Section: Discussionmentioning

confidence: 99%

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Doenhardt

Gano

Sorg

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…While some data has shown Omicron to lead to higher morbidity among unvaccinated and/or previously uninfected children as compared to influenza/ parainfluenza infections [8], our register did not include data regarding vaccination status, prior COVID-19 disease and/or comorbidities. According to Edwards et al, Omicron is independently associated with ICU admission and severe disease, as defined by the WHO Clinical Progression Scale in children without SARS-CoV-2 immunization or prior COVID-19 infection [9].…”

Section: Discussionmentioning

confidence: 99%

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Doenhardt¹,

Gano²,

Sorg³

et al. 2022

Preprint

View full text Add to dashboard Cite

(1) Background: When the Omicron variant of SARS-CoV-2 first emerged in Germany in January 2022, data on related disease severity among children and adolescents was not yet available. Given Omicron’s high transmissibility, the ability to assess its impact on admission and hospitalization rates in children’s hospitals is critical for the purpose of understanding the scope of its burden on the German health care system. (2) Methods: From January 24, 2022 to July 31, 2022, SARS-CoV-2 cases admitted to German pediatric hospitals were monitored via a national, clinician-led reporting system (CLRS) established by the German Society for Pediatric Infectious Diseases (DGPI). Cases treated on general wards and intensive care units, as well as patient age and need for respiratory support were recorded. (3) Results: From January to July 2022, a median of 1.7 cases (range 0.4–3) per reporting pediatric hospital per day were hospitalized on general wards, whereas a median of 0.1 cases (range 0–0.4 cases) were on intensive care units. Of all hospitalized patients, 4.2% received respiratory support. (4) Conclusions: Despite the high incidence rates documented in connection with the Omicron variant in early 2022, the number of pediatric hospital admissions, and especially the number of cases with need for intensive care treatment and respiratory support due to a symptomatic SARS-CoV-2 infection, remained relatively low. Higher Omicron incidence rates had only a modest impact on SARS-CoV-2-related admissions and hospitalization in German children’s hospitals.

show abstract

“…24,25 A major Omicron wave predominated by the highly transmissible BA.2 in HK caused many pediatric hospitalizations, clinical complications and deaths in early 2022 despite the continuation of the elimination strategy that had suppressed SARS-CoV-2 circulation in the past. 1,6 During this BA.2 wave, essentially all hospitalized pediatric COVID-19 cases received medical care in public hospitals, all of which utilize the same electronic health software operated by the HK Hospital Authority (HA). The HK Department of Health (DH) had instituted a rigorous tracking system on COVID-19 vaccinations and compulsory reporting of infections.…”

Section: Introductionmentioning

confidence: 99%

“…The SARS-CoV-2 Omicron variant continues to cause millions of COVID-19-associated pediatric hospitalizations, severe disease and death globally. [1][2][3][4] BNT162b2 and CoronaVac are amongst the top most widely used COVID-19 vaccines across the world. 5 In Hong Kong (HK), these two vaccines have been authorized for adolescents since 16 Mar 2021 and then children since 21 Jan 2022, while the third dose of both vaccines for all healthy adolescents and children commenced on 11 Mar 2022 and 14 Apr 2022, respectively (Figure S1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe disease

Duque

Leung

Yip

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Vaccine effectiveness (VE) of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 for pediatric populations that had low exposure to prior SARS-CoV-2 variants needs to be further clarified. This can be studied from the 1.36 million vaccine doses had been administered to 766,601 of 953,400 children and adolescents in Hong Kong (HK) since March 2021 to April 2022. Methods: Using an ecological design leveraging the HK vaccination coverage statistics and public hospital records, this study investigated the VE for children aged 3-11 years and adolescents aged 12-18 years at the population level during the Omicron BA.2 wave from January to April 2022. Findings: VE against COVID-19-associated hospitalization for children was 65.3% for 1 dose of BNT162b2 and 13.0% and 86.1% for 1 and 2 doses of CoronaVac, respectively. For adolescents, VE against COVID-19-associated hospitalization was 60.2% and 82.4% after 1 and 2 doses of BNT162b2 and 30.8% and 90.7% after 1 and 2 doses of CoronaVac, respectively. Protection against moderate-to-severe disease for aged 3-18 was high, with VE of 93.1% and 95.8% after 2 doses of BNT162b2 and CoronaVac, respectively. No COVID-19-associated hospitalization or moderate-to-severe disease occurred for 68,565 children and adolescents who received their third dose. Estimated hospitalizations of children and adolescents averted by vaccination were 68 and 999, respectively, and were 45 and 147 for moderate-to-severe cases. Conclusions: BNT162b2 or CoronaVac provide substantial protection from COVID-19-associated hospitalization and moderate-to-severe disease due to a SARS-CoV-2 variant of concern. Funding: The Providence Foundation.

show abstract

Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections

Cited by 48 publications

References 48 publications

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Burden of Pediatric SARS-CoV-2 Hospitalizations during the Omicron Wave in Germany

Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe disease

Contact Info

Product

Resources

About